ArticleBlood cancer discovery2021
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Open access · bronzeAbstract read
In one paragraph
Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Association between the expression status of programmed cell death ligand 1 and the efficacy of pan-cancer neoadjuvant immune checkpoint blockade.Frontiers in immunology · 2025Pooled it
- Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.Nature communications · 2025Trial
- Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.Clinical and experimental medicine · 2023Trial
- STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma.Oncoimmunology · 2026Article
- Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early stage and relapsed multiple myeloma.Haematologica · 2026Article
- The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy.Life (Basel, Switzerland) · 2026Review
- Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.Materials today. Bio · 2026Review
- Dexamethasone activates anti-tumor immunity in multiple myeloma by dismantling the GR-PPP1CB complex to restore STING/IRF3 signaling.Journal for immunotherapy of cancer · 2026Article
- Design principles for optogenetic-based targeted protein degradation.Synthetic and systems biotechnology · 2026Review
- The PPTC7/BNIP3/NIX axis induces cGAS/STING-mediated senescence and augments CAR-T efficacy by repressing tumor-intrinsic mitophagy.Journal of experimental & clinical cancer research : CR · 2026Article
- Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade.Molecular cancer · 2026Review
- The interplay between autophagy and immunogenic cell death: nanomaterial-based strategies for cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Autophagy Modulates Immunogenic Cell Death in Cancer.Cancers · 2026Review
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.Nature cancer · 2026Article
- Spatiotemporal control of immunogenic cell death: rewiring tumor-immune dialogues for next-generation immunotherapy.Frontiers in immunology · 2026Review
- Proteasomal inhibition compromises microvascular integrity via distinct effects on non-immune endothelial cells and immune cells.Frontiers in immunology · 2026Article
- Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation.Frontiers in immunology · 2026Review
- cGAS-STING signaling pathway as a therapeutic target in human diseases.Chinese medical journal · 2025Review
- Article
- Molecular and immunological determinants of long-term survival in multiple myeloma.Blood advances · 2025Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 7 institutions in 4 countries.
Annamaria GullaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. kenneth_anderson@dfci.harvard.edu annamaria_gulla@dfci.harvard.edu.
Eugenio MorelliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8850-0442
Mehmet K SamurDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Cirino BottaDepartment of Oncohematology, "Annunziata" Hospital, Cosenza, Italy.ORCID 0000-0002-1522-4504
Teru HideshimaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Giada BianchiDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-3673-0104
Mariateresa FulcinitiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Stefano MalvestitiDepartment of Pediatric Hematology and Oncology, Freiburg University Hospital, Freiburg, Germany.
Rao H PrabhalaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Srikanth TalluriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Kenneth WenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Yu-Tzu TaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-6199-3569
Paul G RichardsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Dharminder ChauhanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Tomasz SewastianikDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4603-8517
Ruben D CarrascoDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Nikhil C MunshiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Kenneth C AndersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. kenneth_anderson@dfci.harvard.edu annamaria_gulla@dfci.harvard.edu.
Dana-Farber Cancer Institute · USVA Boston Healthcare System · USBrigham and Women's Hospital · USHarvard University · USInstitute for Transfusion Medicine · USOspedale Annunziata di Cosenza · ITUniversity Medical Center Freiburg · DE
Funding
Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MUNSHI, NIKHIL C. · 2003 to 2023
$45.0MTargeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI RICHARD YOUNG · 2011 to 2026
$32.5MRole of Cytokines in Myeloma PathogenesisR01CA050947 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MITSIADES, CONSTANTINE S. · 1991 to 2018
$5.1MTherapeutically Targeting Plasmacytoid Dendritic Cells in Multiple MyelomaR01CA207237 · NCI · DANA-FARBER CANCER INST · PI ANDERSON, KENNETH C., CHAUHAN, DHARMINDER · 2016 to 2020
$2.0MFunctional and biologic significance of deacetylase3 inhibition in myelomaR01CA178264 · NCI · DANA-FARBER CANCER INST · PI ANDERSON, KENNETH C., HIDESHIMA, TERU · 2014 to 2018
$1.8MFunctional Consequences of Ubiquitin Depletion During B Lymphocyte DifferentiationK08CA245100 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIANCHI, GIADA · 2020 to 2024
$1.0MMOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSEI01BX001584 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MUNSHI, NIKHIL C. · 2013 to 2025
–BLRD VA I01 BX001584NCI NIH HHS K08 CA245100NCI NIH HHS P01 CA155258NCI NIH HHS P50 CA100707NCI NIH HHS R01 CA050947NCI NIH HHS R01 CA178264NCI NIH HHS R01 CA207237
Abstract
Proteasome inhibitor bortezomib induces apoptosis in multiple myeloma (MM) cells, and has transformed patient outcome. Using
Indexed as
Multiple MyelomaAnimalsBortezomibHumansImmunityMembrane ProteinsMiceNucleotidyltransferasesSignal TransductionBortezomibMembrane ProteinsNucleotidyltransferasesbortezomibimmunogenic cell death (ICD)immunotherapymultiple myelomaSTING
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.